CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.
about
RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.Targeting the CCL2-CCR2 signaling axis in cancer metastasisEmerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasisThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer ProgressionEthanol promotes mammary tumor growth and angiogenesis: the involvement of chemoattractant factor MCP-1Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapyKif4A mediate the accumulation and reeducation of THP-1 derived macrophages via regulation of CCL2-CCR2 expression in crosstalking with OSCCChemotherapy and tumor microenvironment of pancreatic cancer.Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cellsRecombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 productionMicroRNAs associated with metastatic prostate cancerDiallyl disulfide inhibits TNFα-induced CCL2 release by MDA-MB-231 cells.Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis.Macrophages homing to metastatic lymph nodes can be monitored with ultrasensitive ferromagnetic iron-oxide nanocubes and a 1.5T clinical MR scanner.Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastasesTumor associated macrophages and neutrophils in tumor progression.A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.The tumor-immune microenvironment and response to radiation therapyChemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactionsIdentification of novel markers for the diagnosis of malignant pleural mesothelioma.Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.Molecular basis of lateral force spectroscopy nano-diagnostics: computational unbinding of autism related chemokine MCP-1 from IgG antibodyMRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticlesMonocyte chemotactic protein-1 promotes the proliferation and invasion of osteosarcoma cells and upregulates the expression of AKTImmune microenvironments in solid tumors: new targets for therapy.Characterization of a Gene Expression Signature in Normal Rat Prostate Tissue Induced by the Presence of a Tumor Elsewhere in the Organ.Clinical significance of serum thymus and activation-regulated chemokine in gastric cancer: potential as a serum biomarker.Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2Knockdown of SOX18 inhibits the proliferation, migration and invasion of hepatocellular carcinoma cells.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-κB ActivityExpression of antigen processing and presenting molecules in brain metastasis of breast cancer.Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism.Blockade of MK2 is protective in inflammation-associated colorectal cancer development.N-methyl-N-nitro-N'-nitrosoguanidine induces the expression of CCR2 in human gastric epithelial cells promoting CCL2-mediated migration.Targeting of CCL2-CCR2-Glycosaminoglycan Axis Using a CCL2 Decoy Protein Attenuates Metastasis through Inhibition of Tumor Cell Seeding.Bone marrow macrophages support prostate cancer growth in bone.The multifaceted actions of PTHrP in skeletal metastasisEnhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
P2860
Q24608385-4C468A0C-FB3C-4327-B26F-2DBBDF6E0A81Q26765184-280883F3-D581-440C-AB78-7ED56F96433FQ28069422-A9E570D6-CF8E-49BC-B172-E70677AA1824Q28076760-2C702923-2F7E-45CB-B53A-663A58DA6F20Q28383305-2CBE2406-1CCC-4E95-8CDD-EF3B2557720EQ29618033-FEBA46C1-343E-4C94-B3A6-516641012839Q33714927-EBDC948C-C886-45CC-90C5-2F355B2F511CQ33876637-FE7D2C0B-D3D8-409D-98CC-5A6E962CE513Q33889144-3B7267E9-5438-46A7-B18B-0471AD4FAB86Q33986185-364CF696-0C60-4D25-8EC8-40AC1ED68462Q34042888-F14FD728-DE10-492B-8E70-8E9C464B6792Q34056943-1F22E7FD-0914-498F-9FCA-6670D88F382BQ34107357-A5679B18-FEB4-4F66-ABE7-44C0F0CF7CE2Q34130478-ADEDECFC-A8CB-4FAB-B0F2-30C17DC9B764Q34132305-D0E3DE4C-C72F-46AE-8F26-0B5AA0845B70Q34306107-075B34DE-1C23-428B-B266-4E49B3E541BFQ34326476-6A04181B-7121-42A7-8BE8-337619E38318Q34444598-33FB4FD6-D73A-4072-A30F-64A89EE7276BQ34477550-A61C2F69-8C5D-4076-A66B-86F131B76435Q34760760-B0AC147C-D259-4A37-BB21-D26406972399Q34963525-5126CBBD-DC92-44B3-A3BF-FA857BC3D376Q34995989-F3AA7862-C741-4F23-BE41-368F076A8DE0Q35196287-710C5394-F243-4F79-B92E-B91EEA4EC0DBQ35628416-C72631E8-55D5-4101-ABA1-51539D44524FQ35642044-5D231FE4-9B81-4900-B13C-D911A1ED34B3Q35664216-0F2BF442-FDF6-4326-A6BC-30EDE9BB9078Q35713297-82495A80-7885-4A10-97A4-EE8803902490Q35723824-BB85D6D1-BFD0-4372-9D8C-EDB96EBA7DB1Q35934472-7E55F376-2817-4083-A42D-5BA2307AB75BQ35980893-F50D2E60-E860-4480-B4FE-D0E7873EC8C5Q35994680-B64A8C4C-E64F-4CB6-97B8-DB2D5E4B46C5Q36002622-CB8E62AE-A760-4296-BBAA-FF4262B051BAQ36006453-D65296D8-559E-4639-8F2F-EC676F6091E5Q36211287-83ED3989-6DDB-468A-BF7F-18EE6DBD5FA5Q36469907-16986680-4660-46DF-8BC9-FA9DB5F4F368Q36520272-C0159944-A673-4F73-9F4D-37ADB42A3EF3Q36527922-49490FDB-A996-4907-9BF9-BE38C51D8665Q36546464-6020752B-CC71-4B1E-8B71-2B06670EA03DQ36593285-55FE75C3-42DF-4588-A9CF-171CA6C3061FQ36709856-5846F9A4-DA28-4174-A73A-12F4E7AC2561
P2860
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.
@en
CC chemokine ligand 2
@nl
type
label
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.
@en
CC chemokine ligand 2
@nl
prefLabel
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.
@en
CC chemokine ligand 2
@nl
P2860
P1476
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.
@en
P2093
Jian Zhang
P2860
P356
10.1016/J.CYTOGFR.2009.11.009
P577
2009-12-14T00:00:00Z